ATAI News and Press, ATAI Life Sciences N.V. From 04/29/24

2024-04-29 13:37:07 ET More on psychedelic drug developers Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin spikes after FDA breakthrough tag for psychedelic therapy Psychedelic stocks gain after FDA priority review for MDMA therapy ...

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. Initial results from the recently completed monotherapy Part 1 of the study were shared in M...

New research has looked into the influence of psychedelic substances on sexual functioning and satisfaction. This comes as scientists learn more about the promising potential of psychedelics in treating mental-health conditions. Various studies have looked into the effectiveness of psilocybin ...

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with s...

Legislators in the House of Representatives in the state of Missouri have awarded preliminary approval to a budget measure that would allocate $10 million from opioid settlement funds to study grants focused on researching psilocybin’s use in treating opioid-use disorder. The initiativ...

2024-04-03 10:47:15 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% Seeking Alpha...

2024-04-03 08:53:52 ET More on premarket gainers & stock Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects SELLAS Life Sciences GAAP EPS of -$1.3...

2024-03-28 11:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ATAI Life Sciences (NASDAQ: ATAI ) just reported results for the fourth quarter of 2023. ATAI Life Sciences reported earnings per share of -12 cents. This was above the an...

2024-03-28 07:18:08 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% Seeking Alpha...

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durabl...